Switch theme
Sign up to access all valuation multiples
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics.
2009
8
LTM Revenue $0.8M
LTM EBITDA -$6.1M
$26.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Acarix has a last 12-month revenue (LTM) of $0.8M and a last 12-month EBITDA of -$6.1M.
In the most recent fiscal year, Acarix achieved revenue of $0.6M and an EBITDA of -$6.5M.
Acarix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Acarix valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.8M | XXX | $0.6M | XXX | XXX | XXX |
| Gross Profit | $0.7M | XXX | $0.6M | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | -$6.1M | XXX | -$6.5M | XXX | XXX | XXX |
| EBITDA Margin | -769% | XXX | -1012% | XXX | XXX | XXX |
| EBIT | -$6.5M | XXX | -$6.8M | XXX | XXX | XXX |
| EBIT Margin | -819% | XXX | -1070% | XXX | XXX | XXX |
| Net Profit | -$6.2M | XXX | -$6.8M | XXX | XXX | XXX |
| Net Margin | -775% | XXX | -1067% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Acarix's stock price is SEK 0 (or $0).
Acarix has current market cap of SEK 285M (or $29.4M), and EV of SEK 254M (or $26.2M).
See Acarix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26.2M | $29.4M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Acarix has market cap of $29.4M and EV of $26.2M.
Acarix's trades at 41.0x EV/Revenue multiple, and -4.0x EV/EBITDA.
Equity research analysts estimate Acarix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Acarix has a P/E ratio of -4.8x.
See valuation multiples for Acarix and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $29.4M | XXX | $29.4M | XXX | XXX | XXX |
| EV (current) | $26.2M | XXX | $26.2M | XXX | XXX | XXX |
| EV/Revenue | 32.9x | XXX | 41.0x | XXX | XXX | XXX |
| EV/EBITDA | -4.3x | XXX | -4.0x | XXX | XXX | XXX |
| EV/EBIT | -4.0x | XXX | -3.8x | XXX | XXX | XXX |
| EV/Gross Profit | 37.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.8x | XXX | -4.3x | XXX | XXX | XXX |
| EV/FCF | -3.9x | XXX | -4.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAcarix's last 12 month revenue growth is 245%
Acarix's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.9M for the same period.
Acarix's rule of 40 is -950% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Acarix's rule of X is -156% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Acarix and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 245% | XXX | 185% | XXX | XXX | XXX |
| EBITDA Margin | -769% | XXX | -1012% | XXX | XXX | XXX |
| EBITDA Growth | -20% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -950% | XXX | -767% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -156% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 409% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1160% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Acarix acquired XXX companies to date.
Last acquisition by Acarix was XXXXXXXX, XXXXX XXXXX XXXXXX . Acarix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Acarix founded? | Acarix was founded in 2009. |
| Where is Acarix headquartered? | Acarix is headquartered in Sweden. |
| How many employees does Acarix have? | As of today, Acarix has 8 employees. |
| Is Acarix publicy listed? | Yes, Acarix is a public company listed on STO. |
| What is the stock symbol of Acarix? | Acarix trades under ACARIX ticker. |
| When did Acarix go public? | Acarix went public in 2016. |
| Who are competitors of Acarix? | Similar companies to Acarix include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Acarix? | Acarix's current market cap is $29.4M |
| What is the current revenue of Acarix? | Acarix's last 12 months revenue is $0.8M. |
| What is the current revenue growth of Acarix? | Acarix revenue growth (NTM/LTM) is 245%. |
| What is the current EV/Revenue multiple of Acarix? | Current revenue multiple of Acarix is 32.9x. |
| Is Acarix profitable? | Yes, Acarix is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Acarix? | Acarix's last 12 months EBITDA is -$6.1M. |
| What is Acarix's EBITDA margin? | Acarix's last 12 months EBITDA margin is -769%. |
| What is the current EV/EBITDA multiple of Acarix? | Current EBITDA multiple of Acarix is -4.3x. |
| What is the current FCF of Acarix? | Acarix's last 12 months FCF is -$6.7M. |
| What is Acarix's FCF margin? | Acarix's last 12 months FCF margin is -841%. |
| What is the current EV/FCF multiple of Acarix? | Current FCF multiple of Acarix is -3.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
